DrugBiological

Atigotatug/Nivolumab clinical trials

Also written BMS-986489.

studies test it: 3
open now: 1
in phase 3: 1
first study started: 2025

How each study uses Atigotatug/Nivolumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Atigotatug/Nivolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BMS-986489: 2

By phase

A phase 1/2 study counts in both.

Phase 1: 1
Phase 2: 1
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Small Cell Lung Carcinoma: 2

Who runs them

Industry 2 · Other 1

Bristol-Myers Squibb (2) · SCRI Development Innovations, LLC (1)

Related medicines

As reviewed, each with the page that says it.

One of Immune checkpoint inhibitors source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test Atigotatug/Nivolumab, phase 3 first.

Aug 2027A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Phase 3 · Bristol-Myers Squibb

Studies

Open first, then newest update. How each study uses Atigotatug/Nivolumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.